Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.

Key facts

Study ID

NCT03088267

Run by

Tris Pharma, Inc.

People needed

18

Starts

2017-02-11

Expected to finish

2017-10-30

Last updated by the study team

2019-07-22

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females aged 6 to 12 years at the time of screening, inclusive
• Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly diagnosed with ADHD using the DSM-5 criteria for ADHD
• An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of the following categories:
• Hyperactive-impulsive subscale,
• Inattentive subscale, or
• Total score. Subjects who do not meet this criteria at screening can have ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a minimum of 24 hours prior to baseline.
• In the clinical judgment of the Investigator, the subject must be in need of pharmacological treatment for ADHD.
• Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at screening
• Provide written informed consent (parent/guardian) and assent (child aged 10 - 12 years only) prior to participation in the study

You may not qualify if…

• Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders, oppositional defiant disorder, elimination disorders, and sleep disorders
• Known history of chronic medical illnesses including severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of sudden death
• Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ two times the upper limit of normal, blood urea nitrogen, or creatinine).
• Clinically significant abnormal ECG or cardiac findings on physical examination (including the presence of a pathologic murmur)
• Use of the following medications within 30 days of Baseline Visit:
• MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine)
• Tricyclic Antidepressants (e.g. Desipramine, protriptyline)
• Use of the following medications within 3 days of Baseline Visit
• Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid)
• Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts)
• Use of atomoxetine within 14 days of Baseline Visit
• Planned use of prohibited drugs or agents from the Screening visit through the end of the study
• Abnormal clinically significantly laboratory test value at screening that, in the opinion of the Investigator, would preclude study participation
• Known history of allergy/hypersensitivity to amphetamine or any of the components of Dyanavel XR, or topical anaesthetics
• Known history of lack of response to amphetamine
• Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff.
• Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation
• History of significant illness requiring hospitalization, or surgery requiring anaesthetics within 30 days of Baseline Visit

Where it is running

• Center for Psychiatry and Behavioral Medicine — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.